11 To 14 Amino Acid Residues In Defined Sequence Patents (Class 530/327)
-
Patent number: 8906844Abstract: The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.Type: GrantFiled: August 1, 2008Date of Patent: December 9, 2014Assignee: Biogen Idec Hemophilia Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell
-
Patent number: 8906865Abstract: This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs, or derivatives thereof for treatment of inflammation and/or endotoxic shock and/or treatment of wounds and/or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and/or endotoxic shock, and/or wounds, or for the reduction or levels of inflammatory mediators.Type: GrantFiled: March 25, 2008Date of Patent: December 9, 2014Assignee: ISIS Innovation LimitedInventors: David R. Greaves, Andreas Russ, Jenna L. Cash
-
Publication number: 20140356344Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: August 20, 2014Publication date: December 4, 2014Applicant: BioAtla LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Publication number: 20140357578Abstract: Compositions, methods, and kits are provided for reduction of (CAG)n-RNA mediated toxicity. Compositions, methods, and kits are also provided for treatment of polyglutamine diseases.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicant: The Chinese University of Hong KongInventor: Ho Yin Edwin Chan
-
Publication number: 20140357549Abstract: The present invention relates to inhibitors of Nox1-dependent reactive oxygen species production and their use in the treatment of disorders associated with reactive oxygen species, such as hypertension and cancer.Type: ApplicationFiled: May 13, 2014Publication date: December 4, 2014Applicant: University of Pittsburgh - Of The Commonwealth System of Higher EducationInventors: Daniel J. Ranayhossaini, Patrick Joseph Pagano
-
Publication number: 20140356409Abstract: Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described.Type: ApplicationFiled: December 21, 2012Publication date: December 4, 2014Inventor: Patrick M. Schlievert
-
Publication number: 20140356320Abstract: The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.Type: ApplicationFiled: July 23, 2012Publication date: December 4, 2014Applicant: Universität ZürichInventors: Ilijas Jelcic, Roland Martin, Sven Schippling, Mireia Sospedra, Sara Yousef
-
Publication number: 20140357512Abstract: The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker peptides, which are acetylated, for multiple myeloma. Alternatively, the biomarkers are drug specific, HDAC6 biomarker peptides, which are acetylated or unacetylated, for multiple myeloma. The invention also relates to a kit comprising a detection agent and instructions for identifying a biomarker peptide of the invention. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.Type: ApplicationFiled: June 3, 2014Publication date: December 4, 2014Applicant: ACETYLON PHARMACEUTICALS, INC.Inventors: Min Yang, Simon S. Jones
-
Patent number: 8901082Abstract: An immunity-inducing agent comprising as an effective ingredient(s) at least one polypeptide selected from the following polypeptides, the polypeptide(s) having an immunity-inducing activity/activities, or as an effective ingredient(s) a recombinant vector(s) which comprise(s) a polynucleotide(s) encoding the polypeptide(s) and is/are capable of expressing the polypeptide(s) in vivo can be used for therapy and/or prophylaxis of cancer: (a) a polypeptide consisting essentially of not less than 7 consecutive amino acids in any one of the amino acid sequences shown in the odd number IDs of SEQ ID NOs:3 to 95 in SEQUENCE LISTING; (b) a polypeptide having a sequence identity of not less than 90% with the polypeptide (a) and consisting essentially of not less than 7 amino acids; and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof.Type: GrantFiled: July 10, 2009Date of Patent: December 2, 2014Assignee: Toray Industries, Inc.Inventors: Fumiyoshi Okano, Masaki Shimizu, Takanori Saito
-
Patent number: 8901071Abstract: The present invention relates to peptides and their use in the treatment of microbial infections, in particular bacterial infections. In particular, the invention relates to peptides wherein at least 75% of the amino acids of the peptide are arginine and phenylalanine amino acids, at least 50% of the amino acids being arginine amino acids and at least 15% of the amino acids being phenylalanine amino acids.Type: GrantFiled: March 30, 2011Date of Patent: December 2, 2014Assignee: Novabiotics LimitedInventors: Deborah O'Neil, Derry Mercer, Cedric Charrier
-
Publication number: 20140349944Abstract: The present disclosure provides isolated integrin ?L polypeptides, such as ?7 helix polypeptides from the alpha I domain of integrin. Such polypeptides inhibit the interaction between integrin and gp96, thereby inhibiting gp96 activity. Such inhibition can be used to prevent cancer cell growth, cancer metastasis and/or inflammation.Type: ApplicationFiled: May 23, 2014Publication date: November 27, 2014Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENTInventors: Zihai LI, Feng HONG
-
Publication number: 20140349917Abstract: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.Type: ApplicationFiled: April 17, 2014Publication date: November 27, 2014Applicant: C3 JIAN, INC.Inventors: RANDAL H. ECKERT, CHRIS KAPLAN, JIAN HE, DANIEL K. YARBROUGH, MAXWELL ANDERSON, JEE-HYUN SIM
-
Publication number: 20140348822Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.Type: ApplicationFiled: June 10, 2014Publication date: November 27, 2014Inventors: Neil R. Cashman, Avijit Chakrabartty, Rishi Rakhit, Joachim Bernhard Ostermann
-
Publication number: 20140350218Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: ApplicationFiled: April 15, 2014Publication date: November 27, 2014Applicant: THE UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: MAREN WATKINS, BALDOMERO M. OLIVERA, DAVID R. HILLYARD, J. MICHAEL MCINTOSH
-
Publication number: 20140348747Abstract: Provided herein are compositions and methods for the assembly of a bioluminescent complex from two or more non-luminescent (e.g., substantially non-luminescent) peptide and/or polypeptide units. In particular, bioluminescent activity is conferred upon a non-luminescent polypeptide via structural complementation with another, complementary non-luminescent peptide.Type: ApplicationFiled: March 13, 2014Publication date: November 27, 2014Applicant: Promega CorporationInventors: Andrew S. Dixon, Lance Encell, Mary Hall, Keith Wood, Monika Wood, Marie Schwinn, Brock F. Binkowski, Hicham Zegzouti, Nidhi Nath, Subhanjan Mondal, Said Goueli, Poncho Meisenheimer, Thomas Kirkland, James Unch, Dileep K. Pulukkunat, Matthew Robers, Melanie Dart, Thomas Machleidt
-
Patent number: 8895698Abstract: The present invention relates to the field of diagnostics, therapeutics and immunological reagents. More particularly, the present invention provides binding partners of antibodies specific for dendritic cell (DC) antigens. The present invention further provides diagnostic and/or therapeutic agent based on the binding partners or antibodies specific for the binding partners.Type: GrantFiled: September 7, 2012Date of Patent: November 25, 2014Assignee: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventors: Derek Nigel Hart, David Munster, Peter Vukovic
-
Patent number: 8895514Abstract: The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas.Type: GrantFiled: March 15, 2013Date of Patent: November 25, 2014Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffan Walter, Harpreet Singh
-
Patent number: 8895697Abstract: An isolated peptide of 12-20 amino acids in length comprising the amino acid sequence SEQ ID NO:1, wherein the serine residue (S) at position 8 of SEQ ID NO:1 is phosphorylated, is provided. Also provided is a human monophosphorylated alpha-enolase isoform wherein the serine residue (S) at position 419 of the human alpha-enolase amino acid sequence (SEQ ID NO:2) is phosphorylated and in which other post-translational modifications may be present. Further provided are antibodies capable of specifically binding the peptide and/or the isoform of the invention. The peptide, the isoform and the antibodies of the invention may be used in the diagnosis and/or amelioration and/or treatment of pancreatic adenocarcinoma.Type: GrantFiled: September 9, 2010Date of Patent: November 25, 2014Assignee: Natimab Therapeutics S.r.l.Inventors: Francesco Novelli, Barbara Tomaino, Paola Cappello
-
Publication number: 20140341932Abstract: The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.Type: ApplicationFiled: May 14, 2014Publication date: November 20, 2014Inventors: Anthony Robert Milnes Coates, Peter Tormay, Andrew Lightfoot
-
Publication number: 20140342990Abstract: The present invention provides maspin-related compositions and methods of use thereof. In particular, the present invention provides maspin-related compositions, and methods or use thereof, for the promotion of cell adhesion.Type: ApplicationFiled: July 29, 2014Publication date: November 20, 2014Inventor: Ming Zhang
-
Patent number: 8889618Abstract: C-Terminal Fragments of Glucagon-Like Peptide-1 (GLP 1), and methods of use thereof, e.g., for the treatment of obesity and obesity-related disorders, e.g., diabetes and the metabolic syndrome.Type: GrantFiled: November 9, 2009Date of Patent: November 18, 2014Assignee: The General Hospital CorporationInventors: Joel F. Habener, Tatsuya Yano, Eva Tomas Falco
-
Patent number: 8889597Abstract: The present invention provides nucleic acids and peptides, and methods of using the nucleic acids and peptides to identify subjects at risk for a TDP-43 proteinopathy. The invention also provides for an army comprising the nucleic acids and peptides of the invention.Type: GrantFiled: January 30, 2009Date of Patent: November 18, 2014Assignee: Washington UniversityInventors: Nigel J. Cairns, Robert H Baloh, Alan Pestronk, Michael A. Gitcho, Alison M. Goate
-
Publication number: 20140335189Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: ApplicationFiled: July 29, 2014Publication date: November 13, 2014Inventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Publication number: 20140336105Abstract: Anti-inflammatory peptides and pharmaceutical compositions including lysine, alanine, leucine and/or valine for treating inflammatory conditions and uses thereof. Anti-inflammatory peptides for treating IgE-mediated allergies and inflammatory conditions caused by a microbial infection including but not limited to sepsis.Type: ApplicationFiled: July 3, 2014Publication date: November 13, 2014Inventors: Yechiel Shai, Avner Fink, Shay Yaari, Tova Waks, Zelig Eshhar, Christopher J. Arnush
-
Publication number: 20140335092Abstract: The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.Type: ApplicationFiled: May 15, 2014Publication date: November 13, 2014Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Brad J. SPELLBERG, Lin LIN, Ashraf IBRAHIM, Guanpingsheng LUO
-
Publication number: 20140335117Abstract: The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses.Type: ApplicationFiled: October 5, 2012Publication date: November 13, 2014Inventors: Mogens Ryttergaard Duch, Shervin Bahrami
-
Publication number: 20140336129Abstract: A compound can destabilize a binding interaction between an epidermal growth factor receptor (EGFR) and a sodium/glucose co-transporter 1 (SGLT 1). In one embodiment, the compound is a peptide derived from the interacting domain of EGFR. In another embodiment, the peptide is administered to a patient to treat cancer.Type: ApplicationFiled: May 8, 2014Publication date: November 13, 2014Applicant: The University of Houston SystemInventor: Zhang Weihua
-
Publication number: 20140336069Abstract: Peptides useful in determining the presence of autoantibodies in patients suffering from rheumatoid arthritis are disclosed.Type: ApplicationFiled: May 23, 2014Publication date: November 13, 2014Applicant: STICHTING VOOR DE TECHNISCHE WETENSCHAPPENInventors: Waltherus Jacobus Wilhelmus VAN VENROOIJ, Jan Wouter DRIJFHOUT, Martinus Adrianus Maria VAN BOEKEL, Gerardus Jozef Maria PRUIJN
-
Patent number: 8884214Abstract: Methods of using halogenated peptides as internal standards for liquid chromatography-mass spectrometry, and novel halogenated peptides useful for the same, are disclosed. In particular, methods of using halogenated peptides as internal standards in proteomic analyzes, as well as methods of using halogenated peptides to conduct quality control assessments of and/or to calibrate liquid chromatography-mass spectrometry systems are disclosed.Type: GrantFiled: December 4, 2012Date of Patent: November 11, 2014Assignee: Institute for Systems BiologyInventors: Hamid Mirzaei, Rudolf Aebersold
-
Patent number: 8883963Abstract: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-I receptor agonistic activity.Type: GrantFiled: December 10, 2008Date of Patent: November 11, 2014Assignee: Cadila Healthcare LimitedInventors: Rajesh H. Bahekar, Mukul R. Jain, Pankaj Ramanbhai Patel
-
Patent number: 8883721Abstract: The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18 (SEQ ID NO: 93), wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.Type: GrantFiled: May 12, 2010Date of Patent: November 11, 2014Assignees: McGill University, The Administrators of the Tulane Educational FundInventors: Cyril Y. Bowers, David H. Coy, Simon J. Hocart, Gloria S. Tannenbaum
-
Patent number: 8883740Abstract: Compositions for regenerating tissue and wound repair, among other applications, are described.Type: GrantFiled: January 22, 2009Date of Patent: November 11, 2014Assignees: Fundacao de Amparoa Pesquisa do Estado de Sao Paulo-Fapesp, Biolab Sanus Farmaceutica Ltda.Inventors: Janaina De Souza Ventura, Linda Christian Carrijo Carvalho, Ana Marisa Chudzinski-Tavassi
-
Patent number: 8883413Abstract: Compounds comprising peptides and peptidomimetics capable of binding the C3 protein and inhibiting complement activation are disclosed. These compounds display improved complement activation-inhibitory activity as compared with currently available compounds. Isolated nucleic acid molecules encoding the peptides are also disclosed.Type: GrantFiled: July 6, 2011Date of Patent: November 11, 2014Assignee: The Trustees of the University of PennsylvaniaInventor: John D. Lambris
-
Patent number: 8883964Abstract: The invention provides modified collagen and related therapeutic and diagnostic methods.Type: GrantFiled: September 6, 2012Date of Patent: November 11, 2014Assignee: The Johns Hopkins UniversityInventors: Michael Yu, Jennifer H. Elisseeff, Allen Yi-Lan Wang, Hyeseung Janice Lee, Xiao Mo
-
Publication number: 20140328831Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.Type: ApplicationFiled: March 24, 2014Publication date: November 6, 2014Inventors: William D. Carlson, Peter C. Keck
-
Publication number: 20140329737Abstract: The present invention relates to an improved macromolecule transduction domain (MTD), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved MTD according to the present invention, compared to an existing MTD, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like. Additionally, the improved MTD can be very useful in development of new drugs and incrementally modified drugs as uses of the improved MTD are possible in drug delivery systems, recombinant protein vaccines or DNA/RNA therapeutic agents, gene or protein therapies, and pharmacologically or medically useful protein production or medical, pharmacological and pharmaceutical compositions.Type: ApplicationFiled: November 23, 2012Publication date: November 6, 2014Applicant: Procell Therapeutics Inc.Inventors: Ki Deok Shin, Kang Jin Lee, Sunny Lim, Byung Kyu Lee, Jong Rae Kim
-
Publication number: 20140329775Abstract: Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions.Type: ApplicationFiled: February 17, 2014Publication date: November 6, 2014Inventor: Scott G. Petersen
-
Patent number: 8877161Abstract: Compositions and methods relating to interfering with the interaction of gangliosides, such as GM1, with their ligands are provided. For example, methods are provided for treating infections by blocking the infectious agent from binding with GM1 using GM1-like peptides. Also provided are methods of inhibiting ligands from binding to GM1 on the surface of cells and for neutralizing anti-GM1 antibodies in neurological diseases.Type: GrantFiled: October 19, 2012Date of Patent: November 4, 2014Assignee: Georgia Regents Research Institute, Inc.Inventors: Robert Yu, Han-Chung Wu
-
Patent number: 8877738Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antipathogenic, in particular antiviral or/and antibacterial activity. In a preferred aspect, the peptide compounds of the invention have an activity in respect of a broad spectrum of viruses, both DNA and RNA viruses, irrespective of whether they possess virus envelope or not. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, i.e. for the treatment or prevention of pathogenic, in particular viral or/and bacterial infections.Type: GrantFiled: August 5, 2010Date of Patent: November 4, 2014Assignee: Spiderbiotech S.r.L.Inventors: Andrea Giuliani, Giovanna Pirri, Lorena Pizzuto, Santo Landolfo, Giorgio Gribaudo, David Lembo, Davide Gibellini
-
Publication number: 20140322790Abstract: Described herein are methods of detecting a wound infection and for detecting the presence or absence of bacteria, for example, wound bacteria in a sample, by contacting a sample with a peptide substrate derived from the modification of the reactive site loop (RSL) domain of the ?1-proteinase inhibitor. In the current invention, we have demonstrated that these peptide substrates without the alpha 1 protein can be efficiently used as peptide substrates. The modification or the absence of modification of this peptide substrate by the enzyme produced and/or secreted by the bacteria, can serve as an indicator for the presence or absence of the bacteria in the sample. The present invention also features a biosensor for detecting the presence or absence of bacteria in a sample.Type: ApplicationFiled: December 13, 2013Publication date: October 30, 2014Applicant: WOUNDCHEK LABORATORIESInventors: Shite Sebastian, Gerard J. Colpas, Diane L. Ellis-Busby, Jennifer M. Harvard, Mitchell C. Sanders
-
Publication number: 20140322279Abstract: The invention relates to a novel class of self-assembling peptides, compositions thereof, methods for the preparation thereof and methods of use thereof. The invention also encompasses methods for tissue regeneration, increasing the production of extracellular matrix proteins, and methods of treatment comprising administering self-assembling peptides.Type: ApplicationFiled: April 28, 2014Publication date: October 30, 2014Applicant: Massachusetts Institute of TechnologyInventors: Yoshiyuki Kumada, Shuguang Zhang
-
Publication number: 20140322132Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Publication number: 20140323392Abstract: Disclosed herein are compositions and methods for inhibiting viral entry.Type: ApplicationFiled: March 28, 2012Publication date: October 30, 2014Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: J. Nicholas Francis, Joseph S. Redman, Michael S. Kay
-
Publication number: 20140322302Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.Type: ApplicationFiled: May 11, 2014Publication date: October 30, 2014Applicant: COMBIMAB, INCInventors: Henry Wolfe, Reinhard Ebner
-
Publication number: 20140322253Abstract: Compositions and methods are provided for eliciting antigen-specific T-cell responses against human cyclin A1 (CCNA1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (AML) including leukemia stem cells (LSC) and in immunologically privileged testis cells, but not in other normal cell types. CCNA1-derived peptide epitopes that are immunogenic for T-cells including CTL are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells.Type: ApplicationFiled: November 9, 2012Publication date: October 30, 2014Inventors: Philip Greenberg, Sebastian Ochsenreither
-
Publication number: 20140322161Abstract: The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at the most 30 contiguous amino acids chosen from within the complete IL-6 sequence.Type: ApplicationFiled: August 9, 2012Publication date: October 30, 2014Applicant: PEPTINOV SASInventors: Lucille Desallais, Mattieu Montes, Jean-Francois Zagury
-
Patent number: 8871901Abstract: Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals, which include landscape bacteriophage. The disclosed compositions may include immunogenic compositions or vaccines.Type: GrantFiled: March 22, 2011Date of Patent: October 28, 2014Assignee: Auburn UniversityInventors: Tatiana I. Samoylova, Nancy R. Cox, Alexandre M. Samoylov, Anna M. Cochran, Valery A. Petrenko
-
Patent number: 8871719Abstract: Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids.Type: GrantFiled: January 24, 2011Date of Patent: October 28, 2014Assignee: OncoTherapy Science, Inc.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Publication number: 20140314734Abstract: A peptide composition is provi'deo!which specifically inhibits the ability of ? protein kinase C (?PKC) to phosphor/late pyruvate dehydrogenase kinase (PDK) under ischemic conditions. The peptide composition is useful for treating or reducing tissue damage resulting from ischemia and/or reperfusion.Type: ApplicationFiled: August 10, 2012Publication date: October 23, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daria Mochly-Rosen, Nir Qvit, Marie-Helene Disatnik Dziesietnik
-
Publication number: 20140315824Abstract: The subject of the present invention are peptide preparations obtained via the enzymatic digestion of hair, wool, bristles, animal fur and individual peptides with sequences corresponding to individual components of a peptide preparation with antitumour activity, for use in the treatment of tumours or oncological prophylaxis as basal components or components of compositions of substances for treating tumours or components of substances used in oncological prophylaxis.Type: ApplicationFiled: December 6, 2011Publication date: October 23, 2014Applicant: Instytut Medycyny Doswiadczalnej i Klinicznej PanInventors: Andrzej Lipkowski, Sergiusz Markowicz